.. En-situation-néo-adjuvante, 156 1.1. Études de trastuzumab monothérapie / association concomitante chimio ou thérapies ciblées, p.156

C. Noah and . Gianni, Protocole CMF qui n'est plus utilisé en France), p.157

.. Utilisation-du-pertuzumab-en-situation-néo-adjuvante, 158 a, p.158

S. Agelaki, A. Kalykaki, H. Markomanolaki, M. A. Papadaki, G. Kallergi et al., Dimitrios Mavroudis, and Vassilis Georgoulias Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer, PLOS ONE, vol.10, issue.6, 2015.

A. Ahmad, U. Bano, M. Gondal, and A. Khan, Her-2/neu Gene Overexpression in Breast Carcinoma and Its Association with Clinicopathological Characteristics of the Disease, J Coll Physicians Surg Pak, vol.19, pp.297-306, 2009.

A. Alajati, I. Guccini, S. Pinton, R. Garcia-escudero, T. Bernasocchi et al., Interaction of CDCP1 with HER2 Enhances HER2-Driven Tumorigenesis and Promotes Trastuzumab Resistance in Breast Cancer, Cell Reports, vol.11, issue.4, pp.564-76, 2015.
DOI : 10.1016/j.celrep.2015.03.044

S. Anastasi, G. Sala, C. Huiping, E. Caprini, G. Russo et al., Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin, Oncogene, vol.24, issue.28, pp.4540-4588, 2005.
DOI : 10.1038/35052073

. Anne-laure, Classification Histologique et Pathologie Moléculaire, INSERM, 2010.

M. Antoine, M. Teilhac, B. Poulet, and J. Cros, De la cellule mammaire normale ?? la cellule canc??reuse, M??decine Nucl??aire, vol.34, issue.1, pp.14-22, 2010.
DOI : 10.1016/j.mednuc.2009.11.003

L. Arnould, P. Arveux, J. Couturier, M. Gelly-marty, C. Loustalot et al., Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification, Clinical Cancer Research, vol.13, issue.21, pp.6404-6413, 2007.
DOI : 10.1158/1078-0432.CCR-06-3022

S. Arora and E. A. Golemis, A new strategy to ERADicate HER2-positive breast tumors?, Science Signaling, vol.110, issue.7, pp.11-11, 2015.
DOI : 10.1182/blood-2006-11-053728

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483198/pdf

M. Ban, J. Viculin, S. Tomic, V. Capkun, A. Strikic et al., Retrospective Analysis of Efficacy of Trastuzumab in Adjuvant Treatment of, 2016.

M. Barok, H. Joensuu, and J. Isola, Trastuzumab emtansine: mechanisms of action and drug resistance, Breast Cancer Research, vol.49, issue.2, p.209, 2014.
DOI : 10.2967/jnumed.108.051771

R. Bartsch, . Berghoff, Z. Pluschnig, P. Bago-horvath, . Dubsky et al., Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases, British Journal of Cancer, vol.18, issue.1, pp.25-31, 2012.
DOI : 10.1080/02841860500486630

J. Baselga, K. A. Gelmon, S. Verma, A. Wardley, P. Conte et al., Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2???Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy, Journal of Clinical Oncology, vol.28, issue.7, pp.1138-1182, 2010.
DOI : 10.1200/JCO.2009.24.2024

J. Baselga, J. Cortés, S. Kim, S. Im, R. Hegg et al., Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer, New England Journal of Medicine, vol.366, issue.2, pp.109-119, 2012.
DOI : 10.1056/NEJMoa1113216

J. Baselga and S. M. Swain, CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer, Clinical Breast Cancer, vol.10, issue.6, pp.489-91, 2010.
DOI : 10.3816/CBC.2010.n.065

D. Bellet and V. Dangles-marie, Anticorps humanis??s en th??rapeutique, m??decine/sciences, vol.21, issue.12, 2005.
DOI : 10.1051/medsci/200521121054

L. Belmondo, Perspectives des th??rapies cibl??es dans le cancer du sein m??tastatique, Société Française de Pharmacologie et de Thérapeutique, pp.491-503, 2012.
DOI : 10.2515/therapie/2012068

B. Bender, D. D. Leipold, K. Xu, B. Shen, J. Tibbitts et al., A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody???Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer, The AAPS Journal, vol.16, issue.5, pp.994-1008, 2014.
DOI : 10.1208/s12248-014-9618-3

. Errihani, [Predictive Factors of Response to Anthracyclines Neoadjuvant Chemotherapy in Breast Cancer], Gynecologie, Obstetrique & Fertilite, vol.39, issue.2, pp.81-86, 2011.

A. Berman, B. Teig, M. Duracinsky, M. Gayet, M. Bellin et al., Diagnostic en un jour des l??sions du sein??: ??valuation m??dicale et psychologique de la prise en charge?????????tude EVADIASEIN, Journal de Gyn??cologie Obst??trique et Biologie de la Reproduction, vol.45, issue.1, pp.21-28, 2016.
DOI : 10.1016/j.jgyn.2015.01.003

H. Berment, I. Nekka, M. Fischer, F. Ferreira, M. Mohallem et al., Prise en charge du cancer du sein??: quel pr??l??vement pour quel traitement???, Imagerie de la Femme, vol.25, issue.3, pp.182-88, 2015.
DOI : 10.1016/j.femme.2015.06.004

E. Beurel, S. F. Grieco, and R. S. Jope, Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases, Pharmacology & Therapeutics, vol.148, pp.114-145, 2015.
DOI : 10.1016/j.pharmthera.2014.11.016

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340754/pdf

G. Bianchini, L. Pusztai, T. Pienkowski, Y. Im, G. V. Bianchi et al., Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial, Annals of Oncology, 2015.
DOI : 10.1093/annonc/mdv395

F. C. Bidard and J. Pierga, Pertuzumab : Une Nouvelle Option Thérapeutique Dans Le Traitement Des Cancers Du Sein HER2+, La Lettre du cancérologue, vol.21, issue.10, 2012.

K. L. Blackwell, J. Harold, A. M. Burstein, H. S. Storniolo, G. Rugo et al., Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2???Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study, Journal of Clinical Oncology, vol.30, issue.21, pp.2585-2592, 2012.
DOI : 10.1200/JCO.2011.35.6725

J. Blay, Les Cibles Membranaires de La Cellule Tumorale. Thérapie Ciblée Des Cancers, 2010.

M. Boisserie-lacroix, B. Bullier, G. Hurtevent-labrot, S. Ferron, N. Lippa et al., Correlation between imaging and prognostic factors: Molecular classification of breast cancers, Diagnostic and Interventional Imaging, vol.95, issue.2, pp.227-260, 2014.
DOI : 10.1016/j.diii.2013.12.013

H. Bonnefoi, W. Jacot, M. Saghatchian, C. Moldovan, L. Venat-bouvet et al., Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study, Annals of Oncology, vol.26, issue.2, pp.325-357, 2015.
DOI : 10.1093/annonc/mdu551

C. Bonnet, G. Beinse, L. Cabel, D. Cochereau, P. Lavaud et al., ESMO ECCO 2015??: les temps forts de l???immunoth??rapie et des th??rapies cibl??es, Bulletin du Cancer, vol.103, issue.6, pp.594-603, 2016.
DOI : 10.1016/j.bulcan.2016.04.001

C. Bottex-gauthier, . Pollet, D. Favier, and . Vidal, Les Facteurs de Transcription Rel/NF-?B : Rôle Complexe Dans Les Régulations Cellulaires, Pathol Biol, 2002.
DOI : 10.1016/s0369-8114(02)00289-4

F. Bourdeaut and G. Schleiermacher, Hyperexpression, mutation, amplification??? de quoi parle-t-on???, Revue d'Oncologie H??matologie P??diatrique, vol.2, issue.2, 2014.
DOI : 10.1016/j.oncohp.2014.04.002

K. Bouzid, M. Bedairia, and . Marty, Anticorps monoclonaux th??rapeutiques en canc??rologie, Pathologie Biologie, vol.60, issue.4, pp.223-251, 2012.
DOI : 10.1016/j.patbio.2012.05.008

S. W. Brady, J. Zhang, M. Tsai, and D. Yu, PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition, Cancer Biology & Therapy, vol.8, issue.3, pp.402-413, 2015.
DOI : 10.1200/JCO.2005.00.612

URL : http://www.tandfonline.com/doi/pdf/10.1080/15384047.2014.1002693?needAccess=true

T. Brotelle and J. Bay, La voie de signalisation PI3K-AKT-mTOR??: description, d??veloppement th??rapeutique, r??sistances, marqueurs pr??dictifs/pronostiques et applications th??rapeutiques en canc??rologie, Bulletin du Cancer, vol.103, issue.1, pp.18-29, 2016.
DOI : 10.1016/j.bulcan.2015.09.011

N. E. Brown, R. Jeselsohn, T. Bihani, M. G. Hu, P. Foltopoulou et al., Cyclin D1 Activity Regulates Autophagy and Senescence in the Mammary Epithelium, Cancer Research, vol.72, issue.24, pp.6477-89, 2012.
DOI : 10.1158/0008-5472.CAN-11-4139

J. Mcdermott and A. Larkin, Evaluation of IGF1R and Phosphorylated IGF1R as Targets in HER2-Positive Breast Cancer Cell Lines and Tumours, Breast Cancer Research and Treatment, vol.136, issue.3, pp.717-744, 2012.

A. U. Buzdar, V. Valero, N. K. Ibrahim, D. Francis, K. R. Broglio et al., Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen, Clinical Cancer Research, vol.13, issue.1, pp.228-261, 2007.
DOI : 10.1158/1078-0432.CCR-06-1345

. Buzdar and U. Aman, Preoperative chemotherapy treatment of breast cancer???A review, Cancer, vol.9, issue.11, pp.2394-2407, 2007.
DOI : 10.1016/S0093-7754(03)00125-8

K. A. Cadoo, G. Patrick, E. P. Morris, S. Cowell, C. A. Patil et al., Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer, Clinical Breast Cancer, vol.16, issue.6, 2016.
DOI : 10.1016/j.clbc.2016.07.013

Y. Cai, Y. Xi, Z. Cao, G. Xiang, Q. Ni et al., Dual targeting and enhanced cytotoxicity to HER2-overexpressing tumors by immunoapoptotin-armored mesenchymal stem cells, Cancer Letters, vol.381, issue.1, pp.104-116, 2016.
DOI : 10.1016/j.canlet.2016.07.027

M. R. Campbell, H. Zhang, S. Ziaee, A. Ruiz-saenz, N. Gulizia et al., Effective treatment of HER2-amplified breast cancer by targeting HER3 and ??1 integrin, Breast Cancer Research and Treatment, vol.21, issue.4, pp.431-471, 2016.
DOI : 10.1016/j.chembiol.2014.02.011

L. A. Carey, D. A. Berry, C. T. Cirrincione, W. T. Barry, B. N. Pitcher et al., Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib, Journal of Clinical Oncology, vol.34, issue.6, pp.542-591, 2016.
DOI : 10.1200/JCO.2015.62.1268

M. Castel, F. Despas, A. Modesto, C. Gales, B. Honton et al., Effets ind??sirables cardiaques des chimioth??rapies, La Presse M??dicale, vol.42, issue.1, pp.26-39, 2013.
DOI : 10.1016/j.lpm.2012.04.014

A. C. Chen, I. Migliaccio, M. Rimawi, S. Lopez-tarruella, C. J. Creighton et al., Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies, Breast Cancer Research and Treatment, vol.96, issue.12, pp.583-93, 2012.
DOI : 10.1093/jnci/djh166

S. K. Chia, Neoadjuvant and Adjuvant Therapy for HER2 Positive Disease, American Society of Clinical Oncology Educational Book, vol.35, 2015.
DOI : 10.14694/EdBook_AM.2015.35.e41

A. S. Coates, The 14St. Gallen International Breast Cancer Conference Oxfor University Press on Behalf of the European Society for Medical Oncology, Annals of Oncology Advance, 2015.

B. Gebhart and . Thürlimann, Tailoring Therapies?improving the Management of Early Breast Cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015, Annals of Oncology, p.221, 2015.

G. A. Colditz, A. Bernard, F. E. Rosner, and . Speizer, Risk Factors for Breast Cancer According to Family History of Breast Cancer, JNCI: Journal of the National Cancer Institute, vol.88, issue.6, pp.365-371, 1996.
DOI : 10.1093/jnci/88.6.365

C. Copie-bergman, Principes et Application Des Techniques D'hybridation In Situ Fluorescente FISH En Anatomie-Pathologie, UPEC INSERM U955 Créteil, 2011.

F. Coussy and L. Teixeira, Nouveaut??s sur les th??rapies cibl??es dans le cancer du sein, Gyn??cologie Obst??trique & Fertilit??, vol.42, issue.11, pp.787-94, 2014.
DOI : 10.1016/j.gyobfe.2014.09.007

L. Coutte and C. Dreyer, Rôle de La Voie PI3K-AKT-mTOR Dans Le Cancer et Les Thérapeutiques Antitumorales, Bulletin Du Cancer John Libbey Eurotext, vol.99, issue.2, pp.173-80, 2012.

J. Couturier, A. Vincent-salomon, M. Mathieu, A. Valent, and A. Bernheim, Diagnostic de l???amplification du g??ne HER2 dans les cancers du sein, Pathologie Biologie, vol.56, issue.6, pp.375-79, 2008.
DOI : 10.1016/j.patbio.2008.03.009

P. Cremoux and . De, Maruqueurs Pronostiques et Prédictifs de Réponse Aux Traitements Des Cancers Du Sein, Bulletin Du Cancer, issue.11, p.97, 2010.

P. Cremoux, J. De, and . Robert, Signalisation cellulaire et cancer??: caract??risation de cibles th??rapeutiques, Pathologie Biologie, vol.60, issue.4, 2012.
DOI : 10.1016/j.patbio.2012.05.006

A. V. Boddy, Genetic Variants in the HER2 Gene: Influence on HER2 Overexpression and Loss of Heterozygosity in Breast Cancer, European Journal of Cancer, vol.55, pp.27-37, 2016.

R. M. Cubbon and A. R. Lyon, Cardio-oncology: Concepts and practice, Indian Heart Journal, vol.68, pp.77-85, 2016.
DOI : 10.1016/j.ihj.2016.01.022

URL : https://doi.org/10.1016/j.ihj.2016.01.022

D. Amato, L. Valentina, L. Raimondo, M. Formisano, . Giuliano et al., Mechanisms of Lapatinib Resistance in HER2- Driven Breast Cancer, Cancer Treatment Reviews, vol.41, issue.10, pp.877-83, 2015.

C. Dang, N. Iyengar, F. Datko, G. D. Andrea, M. Theodoulou et al., Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2???Positive Metastatic Breast Cancer, Journal of Clinical Oncology, vol.33, issue.5, pp.442-489, 2015.
DOI : 10.1200/JCO.2014.57.1745

E. Daraï, J. Espié, . Gligorov, and . Lecuru, Référentiel Cancers Du Sein 2014 Brochure référentiel, 2014.

. Debska-szmich and . Sylwia, Prognostic Value of HER3, PTEN and P-HER2 Expression in Patients with HER2 Positive Breast Cancer, Postepy Hig Med Dosw, vol.69, pp.586-97, 2015.

R. Demicheli, Tumour dormancy: findings and hypotheses from clinical research on breast cancer, Seminars in Cancer Biology, vol.11, issue.4, pp.297-306, 2001.
DOI : 10.1006/scbi.2001.0385

N. Denduluri, M. R. Somerfield, A. Eisen, J. N. Holloway, A. Hurria et al., Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) ???Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline, Journal of Clinical Oncology, vol.34, issue.20, pp.2416-2443, 2016.
DOI : 10.1200/JCO.2016.67.0182

A. Diallo and C. Prigent, Les Sérine/thréonine Kinases Contrôlant La Progression Du Cycle Cellulaire Comme Cibles Thérapeutiques, Bulletin Du Cancer, vol.98, issue.11, pp.1335-1345, 2011.

A. Dias, W. Claudino, R. Sinha, C. A. Perez, and D. Jain, Human epidermal growth factor antagonists and cardiotoxicity???A short review of the problem and preventative measures, Critical Reviews in Oncology/Hematology, vol.104, pp.42-51, 2016.
DOI : 10.1016/j.critrevonc.2016.04.015

H. Ding, P. R. Gangalum, A. Galstyan, I. Fox, R. Patil et al., HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug, Nanomedicine: Nanotechnology, Biology and Medicine, vol.13, issue.2, 2016.
DOI : 10.1016/j.nano.2016.07.013

URL : https://doi.org/10.1016/j.nano.2016.07.013

M. Dowsett, M. Procter, W. Mccaskill-stevens, E. De-azambuja, U. Dafni et al., Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial, Journal of Clinical Oncology, vol.27, issue.18, pp.2962-69, 2009.
DOI : 10.1200/JCO.2008.19.7939

H. K. Erickson, U. Peter, W. C. Park, Y. V. Widdison, L. M. Kovtun et al., Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing, Cancer Research, vol.66, issue.8, pp.4426-4433, 2006.
DOI : 10.1158/0008-5472.CAN-05-4489

URL : http://cancerres.aacrjournals.org/content/canres/66/8/4426.full.pdf

L. Fang, . Barekati, . Zhang, X. Liu, and . Zhong, Targeted Therapy in Breast Cancer: What's New? " Swiss Medical Weekly, 2011.

S. M. Farabaugh, N. David, A. V. Boone, and . Lee, Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation, Frontiers in Endocrinology, vol.6, 2015.
DOI : 10.3389/fendo.2015.00059

. Rimawi, Resistance to Anti-HER2 Therapies in Breast Cancer, American Society of Clinical Oncology Educational Book, vol.35, 2015.
DOI : 10.14694/EdBook_AM.2015.35.e157

I. S. Fentiman, A. Fourquet, and G. N. Hortobagyi, Male breast cancer, The Lancet, vol.367, issue.9510, pp.595-604, 2006.
DOI : 10.1016/S0140-6736(06)68226-3

A. Ferrari, A. Vincent-salomon, X. Pivot, A. Sertier, E. Thomas et al., A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers, Nature Communications, vol.3, p.12222, 2016.
DOI : 10.1007/BF00994134

URL : https://hal.archives-ouvertes.fr/hal-01388446

D. Fitzpatrick-lewis, N. Hodgson, D. Ciliska, L. Peirson, M. Gauld et al., Breast Cancer Screening Calgary: Canadian Task Force on Preventive Health Care, 2011.

C. Franchet, R. Duprez-paumier, and M. Lacroix-triki, Cancer du sein luminal et apport des classifications intrins??ques mol??culaires : comment identifier les tumeurs luminales A et B en 2015 ?, Bulletin du Cancer, vol.102, issue.6, pp.34-46, 2015.
DOI : 10.1016/S0007-4551(15)31216-9

D. Gajria and S. Chandarlapaty, HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies, Expert Review of Anticancer Therapy, vol.28, issue.2, pp.263-75, 2011.
DOI : 10.1200/JCO.2005.66.130

L. Gianni, 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial, The Lancet Oncology, vol.17, issue.6, pp.791-800, 2016.
DOI : 10.1016/S1470-2045(16)00163-7

J. Gligorov, Polymorphismes et Traitements Néoadjuvants Des Cancers Du Sein: Efficacité Du Docétaxel et Polymorphisme d'ABCB1/MDR1, 2012.

S. Goel and E. P. Winer, HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer: A Paradigm Shift from a Dogma of the Cytotoxic Era, Oncology, vol.29, issue.11, pp.797-797, 2015.

H. L. Gómez, S. Neciosup, C. Tosello, M. Mano, J. Bines et al., A Phase II Randomized Study of Lapatinib Combined With Capecitabine , Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane, 2016.

A. Gonçalves, Combinaisons de Thérapies Anti-HER2 : Deux Balles Pour Une Même Cible!, Bulletin cancer, 2012.

Z. Guan, B. Xu, M. L. Desilvio, Z. Shen, W. Arpornwirat et al., Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2???Overexpressing Metastatic Breast Cancer, Journal of Clinical Oncology, vol.31, issue.16, pp.1947-53, 2013.
DOI : 10.1200/JCO.2011.40.5241

V. Guarneri, A. Frassoldati, A. Bottini, K. Cagossi, G. Bisagni et al., Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2???Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study, Journal of Clinical Oncology, vol.30, issue.16, pp.1989-95, 2012.
DOI : 10.1200/JCO.2011.39.0823

M. Guerin, R. Sabatier, and A. Gonçalves, Autorisation de mise sur le march?? du trastuzumab emtansine (Kadcyla??) dans les cancers du sein m??tastatiques HER2-positifs, Bulletin du Cancer, vol.102, issue.4, pp.390-97, 2015.
DOI : 10.1016/j.bulcan.2015.02.007

S. Guiu, B. Coudert, L. Favier, L. Arnould, and P. Fumoleau, Thérapeutiques Dans Le Cancer Du Sein Métastatique HER2-Positif: Présent et Futur, Bulletin Du Cancer, vol.97, issue.3, pp.365-383, 2010.

S. Guiu, . Gauthier, . Coudert, . Bonnetain, . Favier et al., Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer, British Journal of Cancer, vol.19, issue.9, pp.1335-1377, 2010.
DOI : 10.1200/JCO.2006.09.2775

N. Harbeck, M. W. Beckmann, A. Rody, A. Schneeweiss, V. Müller et al., HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer, Breast Care, vol.8, issue.1, pp.49-55, 2013.
DOI : 10.1159/000346837

N. Harbeck, C. Huang, S. Hurvitz, D. Yeh, Z. Shao et al., Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial, The Lancet Oncology, vol.17, issue.3, pp.357-366, 2016.
DOI : 10.1016/S1470-2045(15)00540-9

A. Harlé, M. Lion, N. Lozano, and J. Merlin, Signification Clinique , Diagnostique et Intérêt Théranostique Des Mutations Du Gène PIK3CA Dans Le Cancer Du Sein, Bulletin Du Cancer, vol.100, issue.10, pp.947-954, 2013.

W. A. Hendrickson and K. B. Ward, Atomic models for the polypeptide backbones of myohemerythrin and hemerythrin, Biochemical and Biophysical Research Communications, vol.66, issue.4, pp.1349-56, 1975.
DOI : 10.1016/0006-291X(75)90508-2

P. Louis and . Goss, Current and Emerging Therapies of HER2-Positive Metastatic Breast Cancer, The Breast, vol.29, pp.170-77, 2016.

C. A. Hudis, Trastuzumab ??? Mechanism of Action and Use in Clinical Practice, New England Journal of Medicine, vol.357, issue.1, pp.39-51, 2007.
DOI : 10.1056/NEJMra043186

M. Tseng, Combination of Everolimus with Trastuzumab plus Paclitaxel as First-Line Treatment for Patients with HER2-Positive Advanced Breast Cancer (BOLERO- 1): A Phase 3, Randomised, Double-Blind, Multicentre Trial, The Lancet Oncology, vol.16, issue.7, pp.816-829, 2015.

. Inca, Assurance maladie, and Ministère de la santé Cancer Du Sein : Quelles Modalités de Dépistage, Pour Quelles Femmes, 2015.

N. Ismaili, R. Belbaraka, A. Elomrani, M. Khouchani, and A. Tahri, Progr??s r??cents dans les th??rapies cibl??es dans le traitement du cancer du sein m??tastatique HER2-positif, La Presse M??dicale, vol.42, issue.11, pp.1461-68, 2013.
DOI : 10.1016/j.lpm.2013.01.066

N. Ismaili, S. Elmajjaoui, A. Tahri, N. Benjaafar, H. Errihani et al., Le trastuzumab dans le traitement adjuvant du cancer du sein, La Presse M??dicale, vol.42, issue.7-8, 2013.
DOI : 10.1016/j.lpm.2013.01.054

C. Jackisch, HER-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based Therapy, The Oncologist, vol.11, issue.suppl_1, pp.34-41, 2006.
DOI : 10.1634/theoncologist.11-90001-34

URL : http://theoncologist.alphamedpress.org/content/11/suppl_1/34.full.pdf

C. Jackisch, R. Hegg, D. Stroyakovskiy, J. Ahn, B. Melichar et al., HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant???adjuvant trastuzumab after 2 years of treatment-free follow-up, European Journal of Cancer, vol.62, pp.62-75, 2016.
DOI : 10.1016/j.ejca.2016.03.087

B. Jiang and L. Liu, Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis, In Advances in Cancer Research, vol.102, pp.19-65, 2009.
DOI : 10.1016/S0065-230X(09)02002-8

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933405/pdf

S. Johnston, J. Pippen, X. Pivot, M. Lichinitser, S. Sadeghi et al., Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor???Positive Metastatic Breast Cancer, Journal of Clinical Oncology, vol.27, issue.33, pp.5538-5584, 2009.
DOI : 10.1200/JCO.2009.23.3734

URL : https://hal.archives-ouvertes.fr/inserm-00484768

R. Khurshid, Phosphorylation Sites of HER2/c-erbB-2: Role in Cell Growth and in Disease, ABP Biochimica Polonica, vol.61, issue.4, pp.699-703, 2014.

B. K. Killelea, B. Anees, N. R. Chagpar, D. R. Horowitz, and . Lannin, Characteristics and treatment of human epidermal growth factor receptor 2 positive breast cancer: 43,485 cases from the National Cancer Database treated in 2010 and 2011, The American Journal of Surgery, vol.213, issue.2, 2016.
DOI : 10.1016/j.amjsurg.2016.05.018

L. Komguem, P. Guilbert, M. Doublier, and F. Guillemin, ??tude de r??ponse histologique du cancer du sein HER2+ apr??s chimioth??rapie n??oadjuvante associant taxane et trastuzumab, Gyn??cologie Obst??trique & Fertilit??, vol.44, issue.7-8, 2016.
DOI : 10.1016/j.gyobfe.2016.06.007

A. Kong, Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen, Oncotarget, vol.7, issue.25, 2016.
DOI : 10.18632/oncotarget.8974

N. B. Kumar, H. Gary, K. Lyman, C. E. Allen, D. V. Cox et al., Timing of weight gain and breast cancer risk, Cancer, vol.67, issue.2, pp.243-243, 1995.
DOI : 10.1016/S0039-6109(16)45179-0

I. Kümler, M. K. Tuxen, and D. Nielsen, A systematic review of dual targeting in HER2-positive breast cancer, Cancer Treatment Reviews, vol.40, issue.2, pp.259-70, 2014.
DOI : 10.1016/j.ctrv.2013.09.002

J. H. Law, G. Habibi, K. Hu, H. Masoudi, Y. Michelle et al., Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival, Cancer Research, vol.68, issue.24, pp.10238-10246, 2008.
DOI : 10.1158/0008-5472.CAN-08-2755

L. Tourneau, C. Paoletti, . Servant, . Bièche, . Gentien et al., Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial, British Journal of Cancer, vol.111, issue.1, pp.17-24, 2014.
DOI : 10.1093/nar/gkq603

L. Tourneau, C. , M. Kamal, A. Tsimberidou, P. Bedard et al., Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials, Journal of the National Cancer Institute, vol.108, issue.4, 2016.
DOI : 10.1093/jnci/djv362

T. Lebret and A. Méjean, Physiopathologie de la m??tastase : du primitif au secondaire, Progr??s en Urologie, vol.18, pp.147-55, 2008.
DOI : 10.1016/S1166-7087(08)74537-8

. Lecomte and . Thierry, Les Anticorps Monoclonaux Thérapeutiques : Une Classe Majeure En Pathologie Digestive, John Libbey Eurotext Hepato Gastro, pp.85-93, 2012.

N. Leone, N. Voirin, L. Roche, F. Binder-foucard, A. Woronoff et al., Rapport Technique, 2015.

X. Li, L. Shen, J. Zhang, J. Su, L. Shen et al., Degradation of HER2 by Cbl-Based Chimeric Ubiquitin Ligases, Cancer Research, vol.67, issue.18, pp.8716-8740, 2007.
DOI : 10.1158/0008-5472.CAN-06-3731

V. Lieutenant, É. Toulza, M. Pommier, and B. Lortal-canguilhem, Herceptin?? (trastuzumab) par voie sous-cutan??e??: une mini r??volution??? ??tude pharmaco-??conomique, Bulletin du Cancer, vol.102, issue.3, pp.270-76, 2015.
DOI : 10.1016/j.bulcan.2015.01.007

D. Liu, M. Shi, C. Duan, H. Chen, Y. Hu et al., Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance, Molecular Immunology, vol.56, issue.1-2, pp.104-116, 2013.
DOI : 10.1016/j.molimm.2013.04.007

Q. Liu, A. Li, Y. Tian, J. D. Wu, Y. Liu et al., The CXCL8-CXCR1/2 pathways in cancer, Cytokine & Growth Factor Reviews, vol.31, pp.61-71, 2016.
DOI : 10.1016/j.cytogfr.2016.08.002

S. Liu, M. De-boeck, H. Van-dam, and . Peter-ten-dijke, Regulation of the TGF-?? pathway by deubiquitinases in cancer, The International Journal of Biochemistry & Cell Biology, vol.76, pp.135-180, 2016.
DOI : 10.1016/j.biocel.2016.05.001

X. Liu, Y. Zheng, C. Qiao, F. Qv, J. Wang et al., Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics, Diagnostic Pathology, vol.11, issue.12, 2015.
DOI : 10.7150/ijms.10038

S. Loibl, G. Von-minckwitz, A. Schneeweiss, S. Paepke, A. Lehmann et al., Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti???Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer, Journal of Clinical Oncology, vol.32, issue.29, pp.3212-3232, 2014.
DOI : 10.1200/JCO.2014.55.7876

I. Lokody, The Lancet Oncology, 2016 ASCO Annual Meeting, 2016.

A. J. Ramírez-ibáñez, N. Romero-díaz, . Piña-lara, R. Víctor, N. O. Campos-garcía et al., Physicochemical and Biological Characterization of a Biosimilar Trastuzumab, BioMed Research International, vol.2015, pp.1-10, 2015.

. Macgrogan, M. Gaëtan, B. Mathieu, F. Poulet, A. Penault-llorca et al., Recommandations du GEFPICS concernant la phase pr??-analytique pour l?????valuation de HER2 et des r??cepteurs hormonaux dans le cancer du sein??: mise ?? jour 2014, Annales de Pathologie, vol.34, issue.5, pp.366-72, 2014.
DOI : 10.1016/j.annpat.2014.08.017

N. Magné, Mécanismes de Résistance Aux Thérapeutiques Moléculaires Ciblées Dans Le Cancer Du Sein : Constats et Perspectives, Bulletin Du Cancer, issue.3, p.97, 2010.

A. Mailliez and P. Vennin, Chimioth??rapie n??oadjuvante dans les cancers du sein??: objectifs, protocoles, ??valuation, impacts, Imagerie de la Femme, vol.20, issue.1, pp.33-37, 2010.
DOI : 10.1016/j.femme.2010.01.002

Y. Maisonnette and J. Sautière, Le Cancer Du Sein, 2009.

H. Marijon and F. André, Her2: Un Modèle de Cible Thérapeutique, Bulletin Du Cancer, vol.98, issue.9, pp.1011-1017, 2011.

M. G. Marmot, D. Altman, D. Cameron, J. Dewar, S. Thompson et al., The benefits and harms of breast cancer screening: an independent review, British Journal of Cancer, vol.15, issue.11, pp.2205-2245, 2013.
DOI : 10.1136/jech.2008.083774

M. Martínez, J. A. Teresa, P. Pérez-fidalgo, J. M. Martín-martorell, V. Cejalvo et al., Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature, Critical Reviews in Oncology/Hematology, vol.97, pp.96-106, 2016.
DOI : 10.1016/j.critrevonc.2015.08.011

D. Mendes, C. Alves, N. Afonso, F. Cardoso, J. Luís-passos-coelho et al., The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer ??? a systematic review, Breast Cancer Research, vol.22, issue.1, 2015.
DOI : 10.1093/annonc/mdq593

E. Mériaux, M. Colombié, and S. Houdebine, Prise en charge du cancer du sein, avanc??es et perspectives, M??decine Nucl??aire, vol.38, issue.5, pp.299-302, 2014.
DOI : 10.1016/j.mednuc.2014.07.007

J. Merlin, Les Inhibiteurs de Tyrosine Kinase En Oncologie, La Lettre Du Pharmacologue, vol.22, issue.2, pp.51-62, 2008.

B. Méry, C. Rancoule, J. Guy, S. Espenel, A. Wozny et al., Cellules souches tumorales??: aspects radioth??rapeutiques et ciblage th??rapeutique, Bulletin du Cancer, vol.103, issue.1, pp.48-54, 2016.
DOI : 10.1016/j.bulcan.2015.10.018

P. D. Mier and J. J. Van-den-hurk, Lysosomal hydrolases of the epidermis., British Journal of Dermatology, vol.243, issue.1, pp.1-10, 1975.
DOI : 10.1001/archderm.101.3.276

K. D. Miller, V. Dieras, N. Harbeck, F. Andre, R. L. Mahtani et al., Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2???Positive, Locally Advanced, or Metastatic Breast Cancer, Journal of Clinical Oncology, vol.32, issue.14, pp.1437-1481, 2014.
DOI : 10.1200/JCO.2013.52.6590

M. M. Moasser, The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis, Oncogene, vol.15, issue.45, pp.6469-87, 2007.
DOI : 10.1158/1078-0432.CCR-04-0112

T. Moatter, M. Aban, W. Iqbal, I. Azam, A. Pervaiz et al., Status of HER2 Amplification, Polysomy 17 and Histopathological Features of 425 Pakistani Breast Cancer Patients, Asian Pac J Cancer Prev, vol.12, issue.11, pp.3069-3073, 2011.

A. J. Evans and J. Albanell, NH2-Terminal Truncated HER-2 Protein but Not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer, Clinical Cancer Research, vol.8, issue.2, pp.347-353, 2002.

K. M. Moore, G. J. Thomas, S. W. Duffy, J. Warwick, R. Gabe et al., Therapeutic Targeting of Integrin v 6 in Breast Cancer, JNCI Journal of the National Cancer Institute, vol.106, issue.8, pp.169-169, 2014.

L. Moreau, Le Cancer Du Sein HER2+, Nouvelles Modalités de Traitement Par Voie Sous-Cutanée, Pôle Santé République, 2014.

C. Moussard, Biochimie Moléculaire -Biochimie Des Communications Cellulaires. 311 vols. Licence Maitrise Doctorat, 2003.

G. Mustacchi, L. Biganzoli, P. Pronzato, F. Montemurro, M. Dambrosio et al., HER2-positive metastatic breast cancer: A changing scenario, Critical Reviews in Oncology/Hematology, vol.95, issue.1, pp.78-87, 2015.
DOI : 10.1016/j.critrevonc.2015.02.002

C. Proteins, SRC-1, AIB1, and NCoR in Breast Cancer, Clinical Cancer Research, vol.11, issue.6, pp.2111-2122

Y. Nagata, K. Lan, X. Zhou, M. Tan, F. J. Esteva et al., PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients, Cancer Cell, vol.6, issue.2, pp.117-127, 2004.
DOI : 10.1016/j.ccr.2004.06.022

V. Nerich, E. Curtit, F. Bazan, P. Montcuquet, C. Villanueva et al., Évaluation Économique de L'utilisation En Routine Du Test Oncotype DX® Dans La Prise En Charge Des Cancers Du Sein En Franche-Comté, Bulletin Du Cancer, vol.101, issue.7, pp.681-689, 2014.

W. Ngamcherdtrakul, D. J. Castro, S. Gu, J. Morry, M. Reda et al., Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment, Cancer Treatment Reviews, vol.45, pp.19-29, 2016.
DOI : 10.1016/j.ctrv.2016.02.005

D. L. Nielsen, I. Kümler, A. E. Jesper, M. Palshof, and . Andersson, Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors, The Breast, vol.22, issue.1, pp.1-12, 2013.
DOI : 10.1016/j.breast.2012.09.008

S. V. Novitskiy, E. Forrester, M. W. Pickup, A. E. Gorska, A. Chytil et al., Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis, Breast Cancer Research, vol.16, issue.5, p.1, 2014.
DOI : 10.1038/nm.2172

O. 'brien, N. A. , K. Mcdonald, L. Tong, E. Von-euw et al., Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT, Clinical Cancer Research, vol.20, issue.13, pp.3507-3527, 2014.
DOI : 10.1158/1078-0432.CCR-13-2769

S. F. Oliveira, M. Vieira-de, R. Ganzinelli, L. Chilà, M. E. Serino et al., Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines, PLOS ONE, vol.27, issue.1, 2016.
DOI : 10.1371/journal.pone.0145647.s003

E. M. Olson, M. Abdel-rasoul, J. Maly, C. S. Wu, N. U. Lin et al., Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab, Annals of Oncology, vol.24, issue.6, pp.1526-1559, 2013.
DOI : 10.1093/annonc/mdt036

E. Paci and . Group, Summary of the Evidence of Breast Cancer Service Screening Outcomes in Europe and First Estimate of the Benefit and Harm Balance Sheet, Journal of Medical Screening, vol.12, issue.4, pp.5-13, 2012.
DOI : 10.1245/s10434-007-9395-7

M. Paillard, E. Curtit, E. Dobi, L. Mansi, F. Bazan et al., Efficacit??, tol??rance et co??t de l?????ribuline chez des patientes pr??sentant un cancer du sein m??tastatique, Bulletin du Cancer, vol.102, issue.9, pp.737-785, 2015.
DOI : 10.1016/j.bulcan.2015.03.021

G. Paintaud, M. Diviné, and P. Lechat, Anticorps monoclonaux ?? usage th??rapeutique : sp??cificit??s du d??veloppement clinique, ??valuation par les agences, suivi de la tol??rance ?? long terme, Th??rapie, vol.67, issue.4, pp.319-346, 2012.
DOI : 10.2515/therapie/2012043

A. H. Partridge, R. B. Rumble, L. A. Carey, S. E. Come, N. E. Davidson et al., Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2???Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline, Journal of Clinical Oncology, vol.32, issue.29, pp.3307-3336, 2014.
DOI : 10.1200/JCO.2014.56.7479

F. Penault-llorca, Cancer Du Sein et HER2, J.Libbey Eurotext, 2003.

B. C. Pestalozzi, Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG), Annals of Oncology, vol.17, issue.6, pp.935-979, 2006.
DOI : 10.1093/annonc/mdl064

M. J. Piccart-gebhart, M. Procter, B. Leyland-jones, A. Goldhirsch, M. Untch et al., Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer, New England Journal of Medicine, vol.353, issue.16, pp.1659-1672, 2005.
DOI : 10.1056/NEJMoa052306

K. Poon, K. Achilles, J. Flagella, J. Beyer, S. Tibbitts et al., Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability, Toxicology and Applied Pharmacology, vol.273, issue.2, pp.298-313, 2013.
DOI : 10.1016/j.taap.2013.09.003

C. C. Portera, J. M. Walshe, D. R. Rosing, N. Denduluri, A. W. Berman et al., Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer, Clinical Cancer Research, vol.14, issue.9, pp.2710-2726, 2008.
DOI : 10.1158/1078-0432.CCR-07-4636

A. Potier, S. Ederhy, Y. Ancedy, A. Etienney, L. Soulat-dufour et al., Strat??gie de d??pistage pr??coce de la toxicit?? cardiaque secondaire aux anthracyclines et th??rapies mol??culaires cibl??es, Bulletin du Cancer, vol.103, issue.7-8, pp.667-73, 2016.
DOI : 10.1016/j.bulcan.2016.05.004

F. Puglisi, C. Fontanella, V. Amoroso, G. V. Bianchi, G. Bisagni et al., Current challenges in HER2-positive breast cancer, Critical Reviews in Oncology/Hematology, vol.98, pp.211-232, 2016.
DOI : 10.1016/j.critrevonc.2015.10.016

C. Racinet, P. Ouellet, F. Charles, and T. Daboval, Neonatal metabolic acidosis at birth: In search of a reliable marker, Gyn??cologie Obst??trique & Fertilit??, vol.44, issue.6, pp.357-62, 2016.
DOI : 10.1016/j.gyobfe.2016.04.005

I. A. Oving, I. Mandjes, and . Kemper, Toxicity of Dual HER2-Blockade with Pertuzumab Added to Anthracycline versus Non-Anthracycline Containing Chemotherapy as Neoadjuvant Treatment in HER2-Positive Breast Cancer: The TRAIN-2 Study, The Breast, vol.29, pp.153-59, 2016.

E. Raymond, Le Concept de Cible En Cancérologie. Thérapie Ciblée Des Cancers, 2009.

J. Rey, S. Fournier, and C. Duc, Analyse de L'expression de L'oncogène HER2 Dans Les Cancers Du Sein, ICHV et CONSILIA, 2006.

D. Robert and B. Vian, Eléments de Biologie Cellulaire, 2013.

J. Robert, Les Itk.pdf, Bulletin Du Cancer, issue.98, pp.1321-1355

L. Rochette, C. Guenancia, A. Gudjoncik, O. Hachet, M. Zeller et al., Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms, Trends in Pharmacological Sciences, vol.36, issue.6, pp.326-374, 2015.
DOI : 10.1016/j.tips.2015.03.005

E. Davidson and . Tan-chiu, Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer, New England Journal of Medicine, vol.353, issue.16, pp.1673-1684, 2005.

R. Roskoski, ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors, Pharmacological Research, vol.87, pp.42-59, 2014.
DOI : 10.1016/j.phrs.2014.06.001

J. S. Ross, K. Wang, C. E. Sheehan, A. B. Boguniewicz, G. Otto et al., Relapsed Classic E-Cadherin (CDH1)-Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations, Clinical Cancer Research, vol.19, issue.10, pp.2668-76, 2013.
DOI : 10.1158/1078-0432.CCR-13-0295

J. S. Ross, L. M. Gay, K. Wang, S. M. Ali, S. Chumsri et al., genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies, Cancer, vol.14, issue.suppl 1, pp.2654-62, 2016.
DOI : 10.2174/1568009614666141111104643

M. Rossi, G. Carioli, M. Bonifazi, A. Zambelli, M. Franchi et al., Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival, European Journal of Cancer, vol.52, pp.41-49, 2016.
DOI : 10.1016/j.ejca.2015.09.012

H. S. Rugo and A. Chien, HER2-positive breast cancer: is more treatment better?, The Lancet Oncology, vol.17, issue.3, pp.268-270, 2016.
DOI : 10.1016/S1470-2045(15)00623-3

M. Scaltriti, F. Rojo, A. Ocana, J. Anido, M. Guzman et al., Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer, JNCI Journal of the National Cancer Institute, vol.99, issue.8, pp.628-666, 2007.
DOI : 10.1093/jnci/djk134

M. Schlageter, Marqueurs Tumoraux Seriques Dans KS actualise1, 2015.

A. Schneeweiss, S. Chia, T. Hickish, V. Harvey, A. Eniu et al., Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA), Annals of Oncology, vol.24, issue.9, pp.2278-84, 2013.
DOI : 10.1093/annonc/mdt182

R. Schulz, . Streller, . Scheel, M. Rüschoff, . Reinert et al., HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer, Cell Death and Disease, vol.18, issue.1, 2014.
DOI : 10.1038/sj.onc.1203277

R. B. Schwab, M. Koehler, S. M. Ali, and B. W. Murray, Genomic profiling and treatment of HER2+, ER+, PgR+ ???triple positive??? breast cancer: A case report and literature review, Cancer Treatment and Research Communications, vol.9, pp.27-31, 2016.
DOI : 10.1016/j.ctarc.2016.06.008

E. Senkus and A. ?acko, Over-treatment in metastatic breast cancer, The Breast, vol.31, 2016.
DOI : 10.1016/j.breast.2016.06.024

. Seol and . Hyesil, Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance, Modern Pathology, vol.41, issue.7, pp.938-986, 2012.
DOI : 10.1016/j.humpath.2009.10.022

C. Serrano, J. Cortes, L. De-mattos-arruda, M. Bellet, P. Gomez et al., Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors, Annals of Oncology, vol.23, issue.4, pp.897-902, 2012.
DOI : 10.1093/annonc/mdr348

D. Shah and C. Osipo, Cancer stem cells and HER2 positive breast cancer: The story so far, Genes & Diseases, vol.3, issue.2, pp.114-137, 2016.
DOI : 10.1016/j.gendis.2016.02.002

URL : https://doi.org/10.1016/j.gendis.2016.02.002

A. Shlien, K. Raine, F. Fuligni, R. Arnold, S. Nik-zainal et al., Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer, Cell Reports, vol.16, issue.7, pp.2032-2078, 2016.
DOI : 10.1016/j.celrep.2016.07.028

K. Sivagnanam, Z. U. Rahman, and T. Paul, Cardiomyopathy Associated With Targeted Therapy for Breast Cancer, The American Journal of the Medical Sciences, vol.351, issue.2, pp.194-199, 2016.
DOI : 10.1016/j.amjms.2015.11.014

D. Slamon, W. Eiermann, N. Robert, T. Pienkowski, and M. Mackey, Adjuvant Trastuzumab in HER2-Positive Breast Cancer, New England Journal of Medicine, vol.365, issue.14, pp.1273-1283, 2011.
DOI : 10.1056/NEJMoa0910383

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268553/pdf

. Slegel and . Peter, Transforming Growth Factor B Signaling Impaires Neu-Induced Mammary Tumorigenesis While Promting Pulmonry Metastasis, PNAS, vol.100, issue.14, pp.8430-8465, 2003.

J. W. Smith, E. Marc, P. Buyse, C. E. Rastogi, S. A. Geyer et al., Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5, Clinical Breast Cancer, vol.17, issue.1, 2016.
DOI : 10.1016/j.clbc.2016.07.008

. Smith, A. Tim, S. M. Phyu, and E. U. Akabuogu, Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells, Anticancer Research, vol.36, issue.1, pp.87-93, 2016.

I. Smith and . Jw, Epirubicin plus Cyclophosphamide Followed by Docetaxel plus Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5, Clinical Breast Cancer, 2016.

A. Sonnenblick, S. Brohée, D. Fumagalli, D. Vincent, D. Venet et al., Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer, BMC Medicine, vol.30, issue.1, pp.10-1186, 2015.
DOI : 10.1200/JCO.2010.31.8907

M. Spielmann, M. Riofrio, and L. Zelek, Facteurs Pronostiques Du Cancer Du Sein et Facteurs Prédictifs de La Réponse Au Traitement, pp.29-35, 2000.

A. M. Storniolo, M. D. Pegram, B. Overmoyer, P. Silverman, N. W. Peacock et al., Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer, Journal of Clinical Oncology, vol.26, issue.20, pp.3317-3340, 2008.
DOI : 10.1200/JCO.2007.13.5202

Z. Sun, Y. Shi, Y. Shen, L. Cao, W. Zhang et al., Analysis of different HER-2 mutations in breast cancer progression and drug resistance, Journal of Cellular and Molecular Medicine, vol.44, issue.12, pp.2691-2701, 2015.
DOI : 10.1093/jjco/hyu053

S. M. Swain, J. Baselga, S. Kim, J. Ro, V. Semiglazov et al., Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer, New England Journal of Medicine, vol.372, issue.8, pp.724-758, 2015.
DOI : 10.1056/NEJMoa1413513

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584549/pdf

P. Szepetowski, D. Perucca-lostanlen, and P. Gaudray, Amplification, proto-oncog??nes et cancers humains, m??decine/sciences, vol.7, issue.1, 1991.
DOI : 10.4267/10608/4272

URL : http://www.ipubli.inserm.fr/bitstream/10608/4272/1/MS_1991_1_14.pdf

Y. Tang, Y. Wang, M. F. Kiani, and B. Wang, Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer, Clinical Breast Cancer, vol.16, issue.5, 2016.
DOI : 10.1016/j.clbc.2016.05.012

B. A. Teicher, What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?, In . American Society of Clinical Oncology, pp.11500117-156, 2015.

L. Teixeira, Principaux Médicaments Utilisés En Chimiothérapie Du Cancer Du Sein, 2015.

C. Thonnon, C. Faure, N. Chopin, F. Beurrier, C. Ho-quoc et al., Int??r??t du bilan d???extension dans le cancer du sein avant chimioth??rapie adjuvante, Bulletin du Cancer, vol.102, issue.5, pp.411-427, 2015.
DOI : 10.1016/j.bulcan.2015.02.018

S. Tiwari, P. Rakesh, J. Mishra, and . Abraham, Neratinib, A Novel HER2-Tar- geted Tyrosine Kinase Inhibitor, Clinical Breast Cancer, 2016.
DOI : 10.1016/j.clbc.2016.05.016

. Tonyali, U. Onder, S. Coskun, M. Yuksel, O. Inanc et al., Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab, The Breast, vol.25, pp.22-26, 2016.
DOI : 10.1016/j.breast.2015.11.006

G. Tortora, Mechanisms of Resistance to HER2 Target Therapy, JNCI Monographs, vol.2011, issue.43, pp.95-98, 2011.
DOI : 10.1093/jncimonographs/lgr026

A. Turpin, A. Mailliez, P. Vennin, and J. Bonneterre, Bilan d???extension des cancers du sein??: r??sultats et cons??quences cliniques, Gyn??cologie Obst??trique & Fertilit??, vol.42, issue.5, pp.325-355, 2014.
DOI : 10.1016/j.gyobfe.2013.11.006

A. Ulas, T. Kos, N. Avci, E. Cubukcu, O. F. Olmez et al., Patients with HER2-positive Early Breast Cancer Receiving Adjuvant Trastuzumab: Clinicopathological Features, Efficacy, and Factors Affecting Survival, Asian Pacific Journal of Cancer Prevention, vol.16, issue.4, 2015.
DOI : 10.7314/APJCP.2015.16.4.1643

D. Uncu, I. V. Bayoglu, M. Ulku-yalcintas-arslan, M. Kucukoner, D. Artac et al., Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study, Asian Pacific Journal of Cancer Prevention, vol.16, issue.9, pp.4127-4158, 2015.
DOI : 10.7314/APJCP.2015.16.9.4127

/. "-upa, O. Pai-1, and . Dwtm, MammaPrint : Valeurs Pronostique et Prédictive Pour Une Utilité Clinique Dans La Prise En Charge Du Cancer Du Sein, 2013. Etat Des Lieux et Des Connaissances . Institut national du cancer

H. Uppal, E. Doudement, K. Mahapatra, W. C. Darbonne, D. Bumbaca et al., Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1), Clinical Cancer Research, vol.21, issue.1, pp.123-156, 2015.
DOI : 10.1158/1078-0432.CCR-14-2093

URL : http://clincancerres.aacrjournals.org/content/clincanres/21/1/123.full.pdf

V. Valero, J. Forbes, M. D. Pegram, T. Pienkowski, W. Eiermann et al., Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens, Journal of Clinical Oncology, vol.29, issue.2, pp.149-56, 2011.
DOI : 10.1200/JCO.2010.28.6450

Z. Varga and A. Noske, Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience, PLOS ONE, vol.33, issue.11, 2015.
DOI : 10.1371/journal.pone.0140652.t002

I. Vasconcelos, A. Hussainzada, S. Berger, E. Fietze, J. Linke et al., The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival, The Breast, vol.29, pp.181-85, 2016.
DOI : 10.1016/j.breast.2016.07.016

R. L. Rugo and . Theriault, Impact of Hormone Receptor Status on Patterns of Recurrence and Clinical Outcomes among Patients with Human Epidermal Growth Factor- 2-Positive Breast Cancer in the National Comprehensive Cancer Network: A Prospective Cohort Study, Breast Cancer Research, vol.14, issue.5, p.1, 2012.

J. F. Viallard, F. Lacombe, F. Belloc, J. L. Pellegrin, and J. Reiffers, M??canismes mol??culaires contr??lant le cycle cellulaire??: aspects fondamentaux et implications en canc??rologie, Cancer/Radioth??rapie, vol.5, issue.2, pp.109-129, 2001.
DOI : 10.1016/S1278-3218(01)00087-7

V. Viassolo, A. Ayme, and P. O. Chappuis, Cancer du sein??: risque g??n??tique, Imagerie de la Femme, vol.26, issue.2, pp.95-104, 2016.
DOI : 10.1016/j.femme.2016.04.009

R. Vicario, V. Peg, B. Morancho, M. Zacarias-fluck, J. Zhang et al., Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies, PLOS ONE, vol.7, issue.6, 2015.
DOI : 10.1371/journal.pone.0129876.s006

S. Vignot, Thérapies Moléculaires Ciblées EMC-Traité de Médecine Akos, 2015.

A. Vincent-salomon, Carcinomes Infiltrants : Facteurs Pronostiques et Prédictifs Pour La Prise de Décisions Thérapeutiques En 2012

T. Vu and F. X. Claret, Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer, Frontiers in Oncology, vol.2, 2012.
DOI : 10.3389/fonc.2012.00062

T. Vu, M. X. Sliwkowski, and F. X. Claret, Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1846, issue.2, pp.353-65, 2014.
DOI : 10.1016/j.bbcan.2014.07.007

N. Areeshi, S. Akhter, and . Haque, Therapeutic Potential and Critical Analysis of Trastuzumab and Bevacizumab in Combination with Different Chemotherapeutic Agents against Metastatic Breast/colorectal Cancer Affecting Various Endpoints, Critical Reviews in OncologyHematology, vol.104, 2016.

H. Wang, Y. Xu, S. Ning, D. Yang, Y. Li et al., The catalytic region and PEST domain of PTPN18 distinctly regulate the HER2 phosphorylation and ubiquitination barcodes, Cell Research, vol.16, issue.9, pp.1067-1090, 2014.
DOI : 10.1152/ajpendo.00185.2011

X. Z. Wang, Q. Liu, J. J. Sun, W. S. Zuo, D. W. Hu et al., Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification, Genetics and Molecular Research, vol.14, issue.2, pp.4282-90, 2015.
DOI : 10.4238/2015.April.28.10

URL : http://doi.org/10.4238/2015.april.28.10

C. Wei, Q. Tan, X. Zhu, F. Qing-hong-qin, Q. Zhu et al., Expression of CDKN1A/p21 and TGFBR2 in Breast Cancer and Their Prognostic Significance, International Journal of Clinical and Experimental Pathology, vol.8, issue.11, p.14619, 2015.

S. T. Wilks, Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway, The Breast, vol.24, issue.5, pp.548-55, 2015.
DOI : 10.1016/j.breast.2015.06.002

D. Wolowiec and M. Ffrench, Kinases d??pendantes des cyclines: r??le biologique et implications dans la pathologie humaine, m??decine/sciences, vol.12, issue.2, 1996.
DOI : 10.4267/10608/707

H. C. Workman, C. Sweeney, and K. L. Carraway, The Membrane Mucin Muc4 Inhibits Apoptosis Induced by Multiple Insults via ErbB2-Dependent and ErbB2-Independent Mechanisms, Cancer Research, vol.69, issue.7, pp.2845-52, 2009.
DOI : 10.1158/0008-5472.CAN-08-2089

URL : http://cancerres.aacrjournals.org/content/canres/69/7/2845.full.pdf

C. Wynne, V. Harvey, C. Schwabe, D. Waaka, C. Mcintyre et al., Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer, The Journal of Clinical Pharmacology, vol.20, issue.2, pp.192-20110, 1177.
DOI : 10.1200/JCO.20.3.719

X. Xu, W. Wang, L. Zhang, Y. Li, M. Tang et al., Expression in Breast Cancer, Asian Pacific Journal of Cancer Prevention, vol.13, issue.10, pp.5033-5069, 2012.
DOI : 10.7314/APJCP.2012.13.10.5033

S. X. Yang, E. Polley, and S. Lipkowitz, New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer, Cancer Treatment Reviews, vol.45, pp.87-96, 2016.
DOI : 10.1016/j.ctrv.2016.03.004

D. A. Yardley, D. John, J. F. Zubkus, R. G. Eakle, L. Bechhold et al., Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute, Clinical Breast Cancer, vol.15, issue.4, pp.251-58, 2015.
DOI : 10.1016/j.clbc.2014.09.007

R. Yerushalmi, K. A. Gelmon, S. Leung, D. Gao, M. Cheang et al., Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes, Breast Cancer Research and Treatment, vol.16, issue.1, pp.131-173, 2012.
DOI : 10.1158/1078-0432.CCR-10-0873

C. D. Young, L. Carlos, R. S. Arteaga, and . Cook, Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers, Breast Cancer Research, vol.68, issue.22, 2015.
DOI : 10.1158/0008-5472.CAN-08-1740

F. Zagouri, E. Bournakis, K. Koutsoukos, and C. A. Papadimitriou, Heat Shock Protein 90 (Hsp90) Expression and Breast Cancer, Pharmaceuticals, vol.106, issue.12, pp.1008-1028, 2012.
DOI : 10.1158/0008-5472.CAN-09-1259

URL : https://doi.org/10.3390/ph5091008

. Azim, Discrepancies between ESMO and NCCN Breast Cancer Guidelines: An Appraisal, The Breast, vol.24, issue.4, pp.513-536, 2015.

D. Zardavas, T. M. Fouad, and M. Piccart, Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015, The Breast, vol.24, pp.143-191, 2015.
DOI : 10.1016/j.breast.2015.07.034

J. Zarzynska and . Magdalena, Two Faces of TGF-Beta1 in Breast Cancer, Mediators of Inflammation, vol.2, issue.2, pp.1-16, 2014.
DOI : 10.1038/nchembio.500

Y. Zemmouri, D. De-croze, R. Vincent-salomon, C. Rouzier, and . Bonneau, Caract??risation mol??culaire des cancers du sein en pratique clinique, Gyn??cologie Obst??trique & Fertilit??, vol.44, issue.5, p.8, 2016.
DOI : 10.1016/j.gyobfe.2016.03.010

W. Zhao, Neuregulin-1 (Nrg1): An Emerging Regulator of Prolactin (PRL) Secretion, Prolactin, 2013.
DOI : 10.5772/54716

Y. Zheng, Y. Yu, B. Chen, J. Hu, T. Jing et al., In-frame Insertion in HER2-positive Breast Cancer, Cancer Investigation, vol.62, issue.3, pp.123-152, 2016.
DOI : 10.1016/0006-2952(73)90196-2